[go: up one dir, main page]

EA201390620A1 - ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ - Google Patents

ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ

Info

Publication number
EA201390620A1
EA201390620A1 EA201390620A EA201390620A EA201390620A1 EA 201390620 A1 EA201390620 A1 EA 201390620A1 EA 201390620 A EA201390620 A EA 201390620A EA 201390620 A EA201390620 A EA 201390620A EA 201390620 A1 EA201390620 A1 EA 201390620A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxazolo
compounds
piridin
ily
pyridin
Prior art date
Application number
EA201390620A
Other languages
English (en)
Other versions
EA021241B1 (ru
Inventor
Дэвид Эндрю Коатес
Рэймонд Гилмоур
Хосе Альфредо Мартин
Эва Мария Мартин Де Ла Нава
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390620(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201390620A1 publication Critical patent/EA201390620A1/ru
Publication of EA021241B1 publication Critical patent/EA021241B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

В настоящем изобретении предложены оксазоло[5,4-b]пиридин-5-ильные соединения, подходящие для лечения рака.
EA201390620A 2010-12-03 2011-11-17 ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ EA021241B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382329 2010-12-03
US201161439151P 2011-02-03 2011-02-03
PCT/US2011/061099 WO2012074761A1 (en) 2010-12-03 2011-11-17 Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer

Publications (2)

Publication Number Publication Date
EA201390620A1 true EA201390620A1 (ru) 2013-10-30
EA021241B1 EA021241B1 (ru) 2015-05-29

Family

ID=46162794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390620A EA021241B1 (ru) 2010-12-03 2011-11-17 ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ

Country Status (27)

Country Link
US (1) US8288548B2 (ru)
EP (1) EP2646445B1 (ru)
JP (1) JP5726321B2 (ru)
KR (1) KR101514162B1 (ru)
CN (1) CN103221415B (ru)
AR (1) AR083868A1 (ru)
AU (1) AU2011337033A1 (ru)
BR (1) BR112013013282A2 (ru)
CA (1) CA2819822C (ru)
CL (1) CL2013001518A1 (ru)
CO (1) CO6761387A2 (ru)
CR (1) CR20130182A (ru)
DO (1) DOP2013000116A (ru)
EA (1) EA021241B1 (ru)
EC (1) ECSP13012653A (ru)
ES (1) ES2567271T3 (ru)
GT (1) GT201300139A (ru)
IL (1) IL226054A0 (ru)
MX (1) MX2013006184A (ru)
NZ (1) NZ610289A (ru)
PE (1) PE20140008A1 (ru)
PH (1) PH12013501115A1 (ru)
SG (1) SG190680A1 (ru)
TW (1) TWI410425B (ru)
UA (1) UA109677C2 (ru)
WO (1) WO2012074761A1 (ru)
ZA (1) ZA201303580B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
CA3078232A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011083A1 (es) 2000-02-15 2001-10-26 Sugen Inc 2-indolinas sustituidas con pirroles inhibidoras de proteinquinasas
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
ATE309997T1 (de) * 2001-03-09 2005-12-15 Pfizer Prod Inc Entzündungshemmende benzimidazolverbindungen
US7320995B2 (en) * 2002-08-09 2008-01-22 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
AU2005251735A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2008282728B2 (en) * 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use

Also Published As

Publication number Publication date
PH12013501115A1 (en) 2013-07-22
DOP2013000116A (es) 2014-10-31
GT201300139A (es) 2014-04-08
EP2646445A1 (en) 2013-10-09
MX2013006184A (es) 2013-07-15
NZ610289A (en) 2015-07-31
IL226054A0 (en) 2013-06-27
PE20140008A1 (es) 2014-01-31
SG190680A1 (en) 2013-07-31
UA109677C2 (ru) 2015-09-25
CA2819822A1 (en) 2012-06-07
EP2646445B1 (en) 2016-03-16
US8288548B2 (en) 2012-10-16
TW201300397A (zh) 2013-01-01
CL2013001518A1 (es) 2013-11-04
ZA201303580B (en) 2014-12-23
AR083868A1 (es) 2013-03-27
JP2013544835A (ja) 2013-12-19
EA021241B1 (ru) 2015-05-29
CR20130182A (es) 2013-07-09
US20120142724A1 (en) 2012-06-07
ES2567271T3 (es) 2016-04-21
CN103221415B (zh) 2015-06-17
CO6761387A2 (es) 2013-09-30
CN103221415A (zh) 2013-07-24
ECSP13012653A (es) 2013-08-30
TWI410425B (zh) 2013-10-01
BR112013013282A2 (pt) 2016-09-06
KR101514162B1 (ko) 2015-04-21
KR20130093140A (ko) 2013-08-21
JP5726321B2 (ja) 2015-05-27
CA2819822C (en) 2015-07-21
WO2012074761A1 (en) 2012-06-07
AU2011337033A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
EA201171367A1 (ru) Винилиндазолильные соединения
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
PH12012502194A1 (en) Indoles
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CR20130539A (es) Triazolopiridinas
EA201400178A1 (ru) Лечение рака молочной железы
CL2015002591A1 (es) Entidades químicas.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
PH12014502032A1 (en) Treatment of brain cancer
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
GB2498325A (en) Modulation neural pathways
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
IL237976A0 (en) A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
UA103197C2 (ru) Применение нифуртимокса для лечения болезней, вызванных трихомонадами
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
WO2012051251A8 (en) Methods of treating giardiasis
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU